2000-11-30T00:00:00
An agent that improves survival in metastatic breast cancer patients has been launched. Herceptin (trastuzumab), a humanised monoclonal antibody, suppresses tumour growth in the 20-30 per cent of metastatic breast cancer patients who overproduce a growth factor called HER2. It binds HER2 receptors on the cancer cell surface so that ...
With a HSJ subscription you’ll unlock:
HSJ is part of Wilmington Healthcare Limited, Beechwood House, 2-3 Commercial Way, Christy Close, Southfields, Essex, SS15 6EF. Company number 2530185. c/o Wilmington plc, 5th Floor, 10 Whitechapel High Street, London E1 8QS. Registered in England and Wales. Company registration 30158470
Site powered by Webvision Cloud